# US 2012/0252735 A1 · Treatment of skin conditions by dickkopf1 (dkk1)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252735 A1
- Document ID: US20120252735A1
- Status: Published application
- Kind: A1
- Application number: 13/492,990
- Filed: 2012-06-11
- Published: 2012-10-04
- Earliest claimed: 2006-12-07
- Assignees: The Govt. of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services
- Inventors: Vincent Hearing; Yuji Yamaguchi; Thierry Passeron
- Web page: https://patentgrep.com/patent/US20120252735A1

## CPC

- A61K 38/1709: {from mammals}
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 35/00: Antineoplastic agents
- A61Q 7/02: Preparations for inhibiting or slowing hair growth
- A61Q 19/02: for chemically bleaching or whitening the skin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present disclosure is generally related to methods of inducing non-palmoplantar skin to develop a palmoplantar phenotype, for example, methods for increasing skin thickness, decreasing skin pigmentation, and/or decreasing hair growth. In particular, disclosed herein are methods of using topical administration of DKK1 to increase skin thickness, decrease skin pigmentation, or reduce hair growth. Also disclosed are topical DKK1 compositions for inducing non-palmoplantar skin to develop a palmoplantar phenotype.

## Claims

### Claim 1

A method for treating a dermatological pathology, comprising:
topically applying an effective amount of DKK1 to non-palmoplantar skin, thereby inducing the non-palmoplantar skin to develop a palmoplantar phenotype and treating the dermatological pathology, wherein the dermatological pathology is a skin graft, an ulcer, an abrasion, an injury caused by a repetitive impact or mechanical stress, age-related skin changes, skin damage due to steroid treatment, uneven skin pigmentation, hyperpigmentation, post-inflammatory pigmentation, fragrance dermatitis, ephelides, vitiligo, a pigmented birthmark, lentigos, or skin changes due to lichen simplex chronicus, melasma, Addison's disease, Peutz-Jeghers syndrome, acanthosis nigricans, hirsutism, congenital adrenal hyperplasia, polycystic ovarian syndrome, hypertrichosis, porphyria cutanea tarda, anorexia nervosa, or melanoma.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method increases skin thickness.

### Claim 3 (depends on 1)

The method of claim 1, wherein the method is an in vitro method.

### Claim 4 (depends on 2)

The method of claim 2, wherein the DKK1 is topically applied to an area of skin in need of thickening on a subject.

### Claim 5 (depends on 4)

The method of claim 4, wherein the subject has a skin graft, an ulcer, an abrasion, an injury caused by a repetitive impact or mechanical stress, age-related skin changes, or skin damage due to steroid treatment.

### Claim 6 (depends on 5)

The method of claim 5, wherein the ulcer is a foot ulcer.

### Claim 7 (depends on 6)

The method of claim 6, wherein the subject has diabetes.

### Claim 8 (depends on 5)

The method of claim 5, wherein the skin graft is on a foot.

### Claim 9 (depends on 5)

The method of claim 5, wherein the area of skin in need of thickening is on a hand.

### Claim 10 (depends on 1)

The method of claim 1, wherein the method reduces skin pigmentation.

### Claim 11 (depends on 10)

The method of claim 10, wherein the DKK1 is topically applied to a pigmented area of skin on a subject.

### Claim 12 (depends on 11)

The method of claim 11, wherein the subject has uneven skin pigmentation, hyperpigmentation, post-inflammatory pigmentation, ephelides, fragrance dermatitis, sun-damaged skin, vitiligo, a pigmented birthmark, lentigos, a café au lait spot, lichen simplex chronicus, melasma, porphyria cutanea tarda, Addison's disease, Peutz-Jeghers syndrome, or acanthosis nigricans.

### Claim 13 (depends on 1)

The method of claim 1, wherein the method reduces hair growth.

### Claim 14 (depends on 13)

The method of claim 13, wherein the DKK1 is topically applied to an area of skin on a subject, wherein unwanted hair is growing on the area of skin.

### Claim 15 (depends on 14)

The method of claim 14, wherein the area of skin is on an upper or lower extremity or is axillary skin.

### Claim 16 (depends on 14)

The method of claim 14, wherein the subject has hirsutism, congenital adrenal hyperplasia, polycystic ovarian syndrome, hypertrichosis, porphyria cutanea tarda, or anorexia nervosa.

### Claim 17 (depends on 1)

The method of claim 1, wherein the method treats or prevents melanoma.

### Claim 18 (depends on 17)

The method of claim 17, wherein the DKK1 is topically applied to an area of skin on a subject, wherein the area of skin contains a pigmented lesion suspected of being a pre-melanoma lesion.

### Claim 19 (depends on 1)

The method of claim 1, wherein topically applying the effective amount of DKK1 to non-palmoplantar skin comprises transdermal administration.

### Claim 20 (depends on 1)

The method of claim 1, wherein the DKK1 is present in a pharmaceutical composition comprising an emulsion.
